Скачать или смотреть Video 21 Targeted Therapies & Biomarkers Beyond PD L1

From HER2 amplification to NTRK and RET fusions, biomarker-driven care is transforming how we treat advanced cervical cancer. This video highlights targeted therapies, antibody-drug conjugates, and molecular profiling that personalize treatment and improve survival.

Understand why biomarker testing—including HER2, NTRK, RET, and high tumor mutational burden (TMB)—is essential for identifying candidates for cutting-edge therapies and clinical trials.

Part of the Pfizer–Genmab funded Cervical Cancer Education and Equity Initiative, this video supports clinicians in providing equitable, guideline-concordant care.

#CervicalCancer #TargetedTherapy #Biomarkers #HER2 #PrecisionOncology #OncologyEducation #CancerCare